CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
celecoxib +3 moredrug
Likely dose
celecoxib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00581971
NCT00581971Phase 2Completed
CompareCT.gov

Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck

University of Alabama at Birmingham·interventional·Posted Dec 28, 2007·Updated Apr 25, 2013

In Brief

A Phase 2 clinical trial evaluating celecoxib, Carboplatin, and 2 other interventions for Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a single-institution, open-label, non-randomized phase IB/II trial of celecoxib administered concurrently with carboplatin, paclitaxel, and radiation therapy in patients with locally advanced or recurrent squamous cell carcinoma of the head and neck.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Pharmacia

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2007
Enrollment StartSep 1, 2002
Primary CompletionDec 1, 2007
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.5 years ago

Interventions

celecoxibdrug

400mg bid starting 1 week before radiotherapy and taken through radiotherapy.

Carboplatindrug

IV, AUC 2.0, weekly for weeks 1 through 7

Paclitaxeldrug

IV 30 mg/m2, weekly for weeks 1 through 7

Radiation Therapyradiation

70.2Gy, at 1.8Gy qd, Monday through Friday